The Centers for Medicare & Medicaid Services (CMS) and the U.S. Food and Drug Administration (FDA) introduced the Rapid Coverage Pathway (RAPID) – a new initiative that streamlines the path from regulatory approval to Medicare coverage for qualifying Breakthrough Devices.
For companies developing innovative healthcare technologies, regulatory clearance and reimbursement remain two of the most significant and uncertain barriers to commercialization. Historically, these processes operated on separate timelines, increasing cost, complexity, and risk.
The RAPID pathway aims to change that and for innovators, the implications are clear:
- Reduced time to reimbursement accelerates commercial viability
- Clearer evidence expectations lower development risk
- Stronger alignment across regulators, payers, and providers improves decision-making
By aligning evidence requirements for FDA approval and Medicare coverage, RAPID enables companies to generate clinical and health-economic data that supports both regulatory and reimbursement decisions in parallel. While the program currently applies only to devices in the FDA’s Breakthrough Devices Program, it marks a meaningful step toward reducing time to patient access.
Philip Yan, Triple Ring’s Manager of Quality Assurance, commented, “For our clients developing Breakthrough Devices, this means evidence strategies can simultaneously support regulatory approval and national coverage, reducing time to reimbursement and de-risking investment in innovation. RAPID enables us to partner with medtech innovators even more strategically – engineering not only to the product requirements, but to the clinical and health‑economic endpoints that matter most to regulators, payers, and ultimately patients.”
The RAPID pathway represents a step toward greater alignment between regulatory approval and Medicare coverage for qualifying Breakthrough Devices.
